Pancreatic cancer: does octreotide offer any promise?
The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies the prognosis of such patients is extremely poor. Despite advances in our understanding of the molecular biology of pancreatic cancer, the systemic treatment of this disease remains unsatisfactory. Systemic chemotherapy and the administration of biologically active molecules such as tumor necrosis factor or interferons have not resulted in significant improvements in response rates or patient survival. New treatment strategies are obviously needed. This paper will discuss current advances in the use of somatostatin analogs in the management of pancreatic cancer.
The Pancreatic Diseases Centre, McGill University Health Centre and Department of Surgery, McGill University, Montreal, Canada. cxlw@musica.mcgill.ca
L
L
Rosenberg
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017481:Receptors, Somatostatin / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D015282:Octreotide